Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemoradiation with or without Surgery in Esophageal Cancer
NCT00193141Phase 2Completed
- Sponsor
- SCRI Development Innovations
- Start
- Oct 1999
- Primary completion
- Oct 2004
- Modality
- DNA Intercalators/Alkylators
01
Overview
Phase 2, randomised, open-label trial of paclitaxel, carboplatin and fluorouracil in esophageal cancer (2 arms), sponsored by SCRI Development Innovations. Primary endpoint: Efficacy of full dose radiation therapy versus preoperative radiation therapy plus surgical resection. Started Oct 1999; status: completed.
02
Drugs
paclitaxelcarboplatinfluorouracil
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT00193141.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00193141.